1-Phenethyl-1-azonia-bicyclo[2.2.2]octane | 73997-40-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Phenethyl-1-azonia-bicyclo[2.2.2]octane
• 英文别名: 1-(2-Phenylethyl)-1-azoniabicyclo[2.2.2]octane
• CAS: 73997-40-7
• 化学式: C₁₅H₂₂N
• 分子量: 216.346
• InChiKey: VWYUFNLVGSBWEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-Phenethyl-1-azonia-bicyclo[2.2.2]octane 在 氢氧化钾 、 potassium chloride 作用下， 以 水 为溶剂， 生成 奎宁环 、 苯乙烯
  参考文献：
  名称：

  Catalysis of the reversible elimination reactions of substituted N-(.beta.-phenylethyl)quinuclidinium ions in aqueous solution

  摘要：

  DOI：

  10.1021/ja00526a047

文献信息

• AZA-BRIDGED-RING COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP2119716A1

  公开（公告）日：2009-11-18

  [PROBLEMS] Provided is a compound which has an antagonistic action on a muscarinic M3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like. [MEANS FOR SOLVING PROBLEMS] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.

  [问题]本发明提供了一种化合物，该化合物对毒蕈碱 M3 受体具有拮抗作用，可用作慢性阻塞性肺病 （COPD）、哮喘等炎症疾病的预防和/或治疗剂的活性成分。 [解决问题的方法]本发明者对一种对毒蕈碱类 M3 受体的结合具有拮抗作用的化合物进行了研究，他们发现一种杂环桥环化合物或其盐对毒蕈碱类 M3 受体的结合具有拮抗作用，从而完成了本发明。本发明的杂环桥环化合物对毒蕈碱类 M3 受体的结合具有拮抗作用，可用作慢性阻塞性肺病（COPD）、哮喘等炎症疾病的预防和/或治疗剂。
• SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES
  申请人：3-DIMENSIONAL PHARMACEUTICALS, INC.

  公开号：EP1442027A1

  公开（公告）日：2004-08-04
• AGGLOMERATE FORMULATIONS INCLUDING ACTIVE PHARMACEUTICAL AGENTS WITH TARGETED PARTICLE SIZES
  申请人：Schering Corporation

  公开号：EP2421518A2

  公开（公告）日：2012-02-29
• [EN] SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES<br/>[FR] DIPHENYLOXAZOLES SUBSTITUES ; SYNTHESE ET UTILISATION COMME SONDES A FLUORESCENCE
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2003031419A1

  公开（公告）日：2003-04-17

  The present invention is directed to a compound of Formula (I); wherein A, R?1, and R2¿ are defined herein. The present invention is also directed to compositions comprising compounds of Formula (I), methods of using compounds of Formula (I), and methods of making compounds of Formula (I).
• [EN] AGGLOMERATE FORMULATIONS INCLUDING ACTIVE PHARMACEUTICAL AGENTS WITH TARGETED PARTICLE SIZES<br/>[FR] PRÉPARATIONS D'AGGLOMÉRAT COMPRENANT DES AGENTS PHARMACEUTIQUES ACTIFS AYANT DES TAILLES DE PARTICULES CIBLÉES
  申请人：SCHERING CORP

  公开号：WO2010124203A2

  公开（公告）日：2010-10-28

  Various embodiments of the present invention provide for an agglomerate comprising at least one active pharmaceutical agent and at least one excipient; wherein at least about ninety percent of the at least one active pharmaceutical agent have a particle size of less than about 2µm.